14
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study

      research-article
      , , , , , , , , , , , , , , , , , , , , , , , , for the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
      Role: Principal Investigator
      Role: Principal Investigator
      Role: Administrative Core Program Manager
      Role: Publications Committee Program Manager
      Role: Administrative Assistant
      Role: Site Principal Investigator
      Role: Research Coordinator
      Role: Research Assistant
      Role: Research Assistant
      Role: Research Assistant
      Role: Research Assistant
      Role: Research Assistant
      Role: Research Assistant
      Role: Research Assistant
      Role: Principal Investigator
      Role: Principal Investigator
      Role: Core Statistician
      Role: Core Statistician
      Role: Core Statistician
      Role: Core Statistician
      Role: Core Statistician
      Role: Site Principal Investigator
      Role: Site Principal Investigator
      Role: Co-Investigator
      Role: Project Manager
      Role: Research Coordinator
      Role: Research Assistant
      Role: Research Assistant
      Role: Principal Investigator
      Role: Principal Investigator
      Role: Clinical Core Program Manager
      Role: Research Coordinator
      Role: Regulatory Specialist
      Role: Research Assistant
      Role: Patient Representative
      Role: Site Principal Investigator
      Role: Co-Investigator
      Role: Research Coordinator
      Role: Research Coordinator
      Role: Research Assistant
      Role: Research Assistant
      Role: Research Assistant
      Role: Site Principal Investigator
      Role: Co-Investigator
      Role: Research Coordinator
      Role: Research Coordinator
      Role: Research Assistant
      Role: Research Assistant
      Role: Research Assistant
      Role: Nurse Coordinator
      Role: Research Assistant
      Role: Research Coordinator
      Role: Research Coordinator
      Role: Research Coordinator
      Role: Research Assistant
      Role: Research Coordinator
      Role: Research Coordinator
      Role: Site Principal Investigator
      Role: Site Principal Investigator
      Role: Co-Investigator
      Role: Research Assistant
      Role: Research Assistant
      Role: Site Principal Investigator
      Role: Co-Investigator
      Role: Research Coordinator
      Role: Research Assistant
      Role: Site Principal Investigator
      Role: Co-Investigator
      Role: Site Program Director
      Role: Research Assistant
      Role: Data Analyst
      Role: Research Assistant
      Role: Administrative Analyst
      Role: Site Principal Investigator
      Role: Site Principal Investigator
      Role: Site Principal Investigator
      Role: Program Manager
      Role: Research Coordinator
      Role: Research Coordinator
      Role: Research Coordinator
      Role: Research Coordinator
      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
      Oxford University Press
      COVID-19, SARS-CoV-2, Long COVID, Delta, Omicron

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Most research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants focuses on initial symptomatology with limited longer-term data. We characterized prevalences of prolonged symptoms 3 months post–SARS-CoV-2 infection across 3 variant time-periods (pre-Delta, Delta, and Omicron).

          Methods

          This multicenter prospective cohort study of adults with acute illness tested for SARS-CoV-2 compared fatigue severity, fatigue symptoms, organ system–based symptoms, and ≥3 symptoms across variants among participants with a positive (“COVID-positive”) or negative SARS-CoV-2 test (“COVID-negative”) at 3 months after SARS-CoV-2 testing. Variant periods were defined by dates with ≥50% dominant strain. We performed multivariable logistic regression modeling to estimate independent effects of variants adjusting for sociodemographics, baseline health, and vaccine status.

          Results

          The study included 2402 COVID-positive and 821 COVID-negative participants. Among COVID-positives, 463 (19.3%) were pre-Delta, 1198 (49.9%) Delta, and 741 (30.8%) Omicron. The pre-Delta COVID-positive cohort exhibited more prolonged severe fatigue (16.7% vs 11.5% vs 12.3%; P = .017) and presence of ≥3 prolonged symptoms (28.4% vs 21.7% vs 16.0%; P < .001) compared with the Delta and Omicron cohorts. No differences were seen in the COVID-negatives across time-periods. In multivariable models adjusted for vaccination, severe fatigue and odds of having ≥3 symptoms were no longer significant across variants.

          Conclusions

          Prolonged symptoms following SARS-CoV-2 infection were more common among participants infected during pre-Delta than with Delta and Omicron; however, these differences were no longer significant after adjusting for vaccination status, suggesting a beneficial effect of vaccination on risk of long-term symptoms.

          Clinical Trials Registration. NCT04610515.

          Abstract

          This prospective study including 2402 SARS-CoV-2–positive participants noted more severe fatigue and ≥3 symptoms at 3 months after acute illness in the pre-Delta cohort compared with Delta and Omicron. However, this was no longer significant after accounting for vaccination status.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection : A Systematic Review

          Question What are the short-term and long-term postacute sequelae of COVID-19 (PASC) infection? Findings In this systematic review of 57 studies comprising more than 250 000 survivors of COVID-19, most sequelae included mental health, pulmonary, and neurologic disorders, which were prevalent longer than 6 months after SARS-CoV-2 exposure. Meaning These findings suggest that long-term PASC must be factored into existing health care systems, especially in low- and middle-income countries. This systematic review estimates organ system–specific frequency and evolution of postacute sequelae of COVID-19 infection. Importance Short-term and long-term persistent postacute sequelae of COVID-19 (PASC) have not been systematically evaluated. The incidence and evolution of PASC are dependent on time from infection, organ systems and tissue affected, vaccination status, variant of the virus, and geographic region. Objective To estimate organ system–specific frequency and evolution of PASC. Evidence Review PubMed (MEDLINE), Scopus, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched from December 2019 through March 2021. A total of 2100 studies were identified from databases and through cited references. Studies providing data on PASC in children and adults were included. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for abstracting data were followed and performed independently by 2 reviewers. Quality was assessed using the Newcastle-Ottawa Scale for cohort studies. The main outcome was frequency of PASC diagnosed by (1) laboratory investigation, (2) radiologic pathology, and (3) clinical signs and symptoms. PASC were classified by organ system, ie, neurologic; cardiovascular; respiratory; digestive; dermatologic; and ear, nose, and throat as well as mental health, constitutional symptoms, and functional mobility. Findings From a total of 2100 studies identified, 57 studies with 250 351 survivors of COVID-19 met inclusion criteria. The mean (SD) age of survivors was 54.4 (8.9) years, 140 196 (56%) were male, and 197 777 (79%) were hospitalized during acute COVID-19. High-income countries contributed 45 studies (79%). The median (IQR) proportion of COVID-19 survivors experiencing at least 1 PASC was 54.0% (45.0%-69.0%; 13 studies) at 1 month (short-term), 55.0% (34.8%-65.5%; 38 studies) at 2 to 5 months (intermediate-term), and 54.0% (31.0%-67.0%; 9 studies) at 6 or more months (long-term). Most prevalent pulmonary sequelae, neurologic disorders, mental health disorders, functional mobility impairments, and general and constitutional symptoms were chest imaging abnormality (median [IQR], 62.2% [45.8%-76.5%]), difficulty concentrating (median [IQR], 23.8% [20.4%-25.9%]), generalized anxiety disorder (median [IQR], 29.6% [14.0%-44.0%]), general functional impairments (median [IQR], 44.0% [23.4%-62.6%]), and fatigue or muscle weakness (median [IQR], 37.5% [25.4%-54.5%]), respectively. Other frequently reported symptoms included cardiac, dermatologic, digestive, and ear, nose, and throat disorders. Conclusions and Relevance In this systematic review, more than half of COVID-19 survivors experienced PASC 6 months after recovery. The most common PASC involved functional mobility impairments, pulmonary abnormalities, and mental health disorders. These long-term PASC effects occur on a scale that could overwhelm existing health care capacity, particularly in low- and middle-income countries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Sequelae in Adults at 6 Months After COVID-19 Infection

            This cohort study analyzed persistent symptoms among adults with coronavirus disease 2019 up to 9 months after illness onset.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection

              Fatigue is a common symptom in those presenting with symptomatic COVID-19 infection. However, it is unknown if COVID-19 results in persistent fatigue in those recovered from acute infection. We examined the prevalence of fatigue in individuals recovered from the acute phase of COVID-19 illness using the Chalder Fatigue Score (CFQ-11). We further examined potential predictors of fatigue following COVID-19 infection, evaluating indicators of COVID-19 severity, markers of peripheral immune activation and circulating pro-inflammatory cytokines. Of 128 participants (49.5 ± 15 years; 54% female), more than half reported persistent fatigue (67/128; 52.3%) at median of 10 weeks after initial COVID-19 symptoms. There was no association between COVID-19 severity (need for inpatient admission, supplemental oxygen or critical care) and fatigue following COVID-19. Additionally, there was no association between routine laboratory markers of inflammation and cell turnover (leukocyte, neutrophil or lymphocyte counts, neutrophil-to-lymphocyte ratio, lactate dehydrogenase, C-reactive protein) or pro-inflammatory molecules (IL-6 or sCD25) and fatigue post COVID-19. Female gender and those with a pre-existing diagnosis of depression/anxiety were over-represented in those with fatigue. Our findings demonstrate a significant burden of post-viral fatigue in individuals with previous SARS-CoV-2 infection after the acute phase of COVID-19 illness. This study highlights the importance of assessing those recovering from COVID-19 for symptoms of severe fatigue, irrespective of severity of initial illness, and may identify a group worthy of further study and early intervention.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clin Infect Dis
                Clin Infect Dis
                cid
                Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
                Oxford University Press (US )
                1058-4838
                1537-6591
                01 June 2023
                27 January 2023
                27 January 2023
                : 76
                : 11
                : 1930-1941
                Affiliations
                Department of Emergency Medicine, Rush University Medical Center , Chicago, Illinois, USA
                Department of Emergency Medicine, University of California , San Francisco, California, USA
                Center for Outcomes Research and Evaluation, Yale School of Medicine , New Haven, Connecticut, USA
                Section of Cardiovascular Medicine, Yale School of Medicine , New Haven, Connecticut, USA
                Center for Outcomes Research and Evaluation, Yale School of Medicine , New Haven, Connecticut, USA
                Department of Epidemiology, Yale School of Public Health , New Haven, Connecticut, USA
                Department of Emergency Medicine, University of California , San Francisco, California, USA
                Department of Emergency Medicine, University of California – San Francisco School of Medicine , San Francisco, California, USA
                Department of Emergency Medicine, Thomas Jefferson University , Philadelphia, Pennsylvania, USA
                Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California – Los Angeles , Los Angeles, California, USA
                Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, Pennsylvania, USA
                Department of Emergency Medicine, UTHealth Houston , Houston, Texas, USA
                Department of Emergency Medicine, UTHealth Houston , Houston, Texas, USA
                Department of Emergency Medicine, University of Texas Southwestern Medical Center , Dallas, Texas, USA
                Center for Outcomes Research and Evaluation, Yale School of Medicine , New Haven, Connecticut, USA
                Section of Cardiovascular Medicine, Yale School of Medicine , New Haven, Connecticut, USA
                Department of Medicine, Division of Infectious Diseases, Rush University Medical Center , Chicago, Illinois, USA
                Department of Emergency Medicine, University of Texas Southwestern Medical Center , Dallas, Texas, USA
                Clinical Informatics Center, University of Texas Southwestern Medical Center , Dallas, Texas, USA
                Department of Global Health, University of Washington , Seattle, Washington, USA
                National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia, USA
                Department of Medicine, Division of Infectious Diseases, Rush University Medical Center , Chicago, Illinois, USA
                National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia, USA
                Department of Global Health, University of Washington , Seattle, Washington, USA
                Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California – Los Angeles , Los Angeles, California, USA
                Center for Outcomes Research and Evaluation, Yale School of Medicine , New Haven, Connecticut, USA
                Department of Emergency Medicine, Yale School of Medicine , New Haven, Connecticut, USA
                Department of Biomedical Informatics and Medical Education, University of Washington , Seattle, Washington, USA
                Department of Psychiatry and Behavioral Sciences, University of Washington , Seattle, Washington, USA
                Department of Medicine, Division of Infectious Diseases, Rush University Medical Center , Chicago, Illinois, USA
                Department of Medicine, Division of Infectious Diseases, Cook County Hospital , Chicago, Illinois, USA
                Author notes

                M. G. and R. C. W. contributed equally to this work.

                R. A. W. and K. A. S. contributed equally to this work.

                Study Group Team Members are listed in Supplementary Appendix 1.

                Correspondence: M. Gottlieb, Department of Emergency Medicine, Rush University Medical Center, 1750 W Harrison St, Kellogg Suite 108, Chicago, IL 60612 ( MichaelGottliebMD@ 123456Gmail.com ).

                Potential conflicts of interest. M. G. reports the following institutional funding: Rush Center for Emerging Infectious Diseases Research Grant, Society for Academic Emergency Medicine Grant, Emergency Medicine Foundation/Council of Residency Directors in Emergency Medicine Education Research Grant, Emergency Medicine: Reviews and Perspectives Medical Education Research Grant, and University of Ottawa Department of Medicine Education Grant. E. S. S. receives grant funding from the National Institute on Minority Health and Health Disparities (U54MD010711-01), the US Food and Drug Administration (FDA) to support projects within the Yale–Mayo Clinic Center of Excellence in Regulatory Science and Innovation (U01FD005938), the National Institute of Biomedical Imaging and Bioengineering (R01 EB028106-01), and the National Heart, Lung, and Blood Institute (R01HL151240); and has received honorarium paid to author for a 1-day educational session from Regeneron. J. G. E. reports serving as Editor in Chief of Adult Primary Care topics for UpToDate. A. V. reports funding for coronavirus disease 2019 (COVID-19)–related studies from the Society of Academic Emergency Medicine Foundation Emerging Infectious Disease and Preparedness Grant, the Agency for Healthcare Research and Quality (R01 HS 28340-01), the FDA (ID: 75F40120C00174), and the Emergency Medicine Health Policy Institute/Emergency Medicine Foundation; grants or contracts from the American Board of Emergency Medicine National Academy of Medicine Fellowship, Centers for Medicare and Medicaid Services, National Institute on Drug Abuse, Moore Foundation, Genentech, and FORE Foundation; consulting fees from Liminal Sciences; payment for expert testimony from Salvi, Shostok & Pritchard; support for attending meetings and/or travel from the American College of Emergency Physician, and stock or stock options with Hyperfine Inc/Liminal Sciences. A. H. I. reports participation on a data and safety monitoring board (DSMB) or advisory board for Stryker, Inc. A. M. C. reports grants or contracts from the CDC, unrelated to this work. L. E. W. reports participation on a DSMB or advisory board for a diabetes project at University of Washington. R. R. reports a grant from the National Institute of Allergy and Infectious Diseases (R01 AI166967-01, all payments made to the University of California, San Francisco). R. A. W. reports consulting fees from UpToDate as a reviewer for infection control sections, and participation as unpaid member of a scientific advisory board for the European Clinical Research Alliance on Infectious Diseases Foundation. S. M. reports an NIH Institutional Training Grant (5KL2TR003981-02), not related to the submitted work. All other authors report no potential conflicts.

                All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

                Author information
                https://orcid.org/0000-0003-3276-8375
                https://orcid.org/0000-0001-5382-9486
                https://orcid.org/0000-0003-1354-1773
                https://orcid.org/0000-0002-7311-6835
                https://orcid.org/0000-0003-4747-381X
                https://orcid.org/0000-0003-2932-4140
                https://orcid.org/0000-0002-8248-0567
                https://orcid.org/0000-0002-3390-858X
                Article
                ciad045
                10.1093/cid/ciad045
                10249989
                36705268
                403d6625-e539-491e-b7d5-7507ecd0970d
                © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 11 November 2022
                : 16 January 2023
                : 22 February 2023
                Page count
                Pages: 12
                Funding
                Funded by: National Center for Immunization and Respiratory Diseases, CDC, DOI 10.13039/100005224;
                Categories
                Major Article
                Original Article
                AcademicSubjects/MED00290

                Infectious disease & Microbiology
                covid-19,sars-cov-2,long covid,delta,omicron
                Infectious disease & Microbiology
                covid-19, sars-cov-2, long covid, delta, omicron

                Comments

                Comment on this article